NCCN Guidelines for Patients® | Multiple Myeloma

74 NCCN Guidelines for Patients ® : Multiple Myeloma, 2018 Index Index active (symptomatic) myeloma 12–13, 32, 39, 42–43 additional treatment 26, 50–52 adjunctive treatment 33, 37, 39, 43, 45 allogeneic stem cell transplant 18, 29, 31–32, 37, 47–48, 50–52 aspiration 16, 19, 20, 30, 45 autologous stem cell transplant 29, 32, 37, 47–48, 50, 52 bisphosphonate 33–34, 45 blood stem cell 8–9, 29–32, 37, 48, 51–52 blood test 14–18, 45 bone damage 12–13, 22–23, 25, 33, 39, 45 bone marrow 8–10, 12–13, 15–16, 19–21, 23, 28–32, 34, 37, 39–40, 43–48 bone marrow biopsy 16, 19, 20 chemotherapy 27–32, 36–37, 43, 48 clinical trial 34–37, 42, 47–48, 51–52, 56 follow-up test 40–43, 45, 47–48, 50 gene 10, 20, 25 imaging test 20–23, 34, 39 kidney damage 13, 17, 33–34, 39, 45 maintenance treatment 26 M-protein 10–13, 18, 33, 39, 41, 45–46, 48 myeloma cell 10–13, 15, 17–18, 20–22, 25, 28, 30, 32, 34, 37, 39–40, 46, 48 plasma cell 6, 8–13, 16, 20, 39, 45–46 primary treatment 26, 32–33, 40–45, 47–48 progressive disease 46–47, 51–52 radiation therapy 25, 32–33, 37, 40, 45 relapse 42–43, 46–48 side effect 15, 25, 28–30, 32–37, 44–45, 48, 50, 52, 56 smoldering (asymptomatic) myeloma 12–13, 39, 41–42 solitary plasmacytoma 10, 13, 16, 20, 25, 37–38, 40–41 stem cell transplant 18, 29–32, 37, 43–44, 47–48, 51–52 supportive care 33, 39, 45, 50 surgery 25–27, 33, 37, 40, 45 symptom 12–13, 15, 18, 25, 33, 37, 39, 41–43, 45–46, 50, 52 targeted therapy 27–29, 36–37, 43 tissue test 19–20 treatment response 41, 45–48, 50–52 urine test 18, 23, 45

RkJQdWJsaXNoZXIy MTE3MTE1